CTEC Global X CleanTech ETF

Healthy Eating Alone Not Enough; Cholesterol Monitoring Is Key HAYWARD, Calif., Nov. 14 /PRNewswire/ -- The possible ban on trans fat for New York City restaurants has sparked a renewed interest in heart health and cholesterol. The concern is valid; studies show a strong correlation between trans fat and LDL, or "bad" cholesterol. According to the American Heart Association, a high level of LDL cholesterol reflects an increased risk of heart disease, the single leading cause of death in America today. (Logo: http://www.newscom.com/cgi-bin/prnh/20060504/NYTH042 ) Doctors recognize the dangers posed by LDL and are making cholesterol checks a standard part of thorough check up. Many are even conducting the tests in their own offices during patient visits while they have the opportunity to offer advice about eating and other lifestyle choices, rather than losing the time associated with sending blood samples to an outside lab for analysis. Point of care testing offers three distinct advantages: convenience, compliance and cost efficiency. "For patients who aren't at their target goals, we are able to make an appointment for educational counseling while they are in our office. And, for those doing well, nothing is better than face to face recognition for trying so hard to control their lifestyle choices, including diet and exercise," said Donna Gemme, Director of Cardiovascular Ambulatory Services at UMass Memorial Medical Center. "We perform point of care cholesterol screening on over 500 patients each month and we rely on the CRMLN-certified LDX(R) System from Cholestech Corporation (NASDAQ:CTEC) to make sure we get lab-accurate results. We conduct a correlation with our hospital lab twice a year, to confirm that our point of care results are on target, and we've always been right on the mark." About the LDX System With accuracy comparable to a reference lab, results using the Cholestech LDX are achieved in five minutes or less. The health professional collects a blood sample using a simple fingerstick, inserts a cassette into the portable LDX system, and receives results within minutes. Patient counseling can begin immediately, while practice efficiency begins to accrue. The LDX is CLIA-waived and is certified to the Cholesterol Reference Method Laboratory Network (CRMLN) standard established by the Centers for Disease Control (CDC). "The possible ban on trans fat has called attention to one of the links between diet and cholesterol, and physicians can respond by offering accurate cholesterol screenings in the office followed immediately by relevant counseling for each patient," said Warren E. Pinkert II, President and CEO of Cholestech. "Point of care equipment is a valuable tool that not only increases compliance, but instrumentation certified to the CRMLN standard, such as the LDX, also offers laboratory accurate results." About Cholestech Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver enzymes at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) System and the GDX(TM) System(1), which is approved for prescription home use and for use in moderate complexity labs, to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes. NOTE: Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the Web at http://www.cholestech.com/. CTEC-G (1) GDX is 510(k) cleared for prescription home use and, accordingly, is CLIA waived. Contact: HLD/Blankman Public Relations (516) 536-6811 Angie Cecil () Julie Gross Gelfand () http://www.newscom.com/cgi-bin/prnh/20060504/NYTH042 http://photoarchive.ap.org/ DATASOURCE: Cholestech Corporation CONTACT: Angie Cecil, , or Julie Gross Gelfand, , both of HLD/Blankman Public Relations, +1-516-536-6811 Web site: http://www.cholestech.com/

Copyright